Document:

EX-4.2

 Exhibit 4.2 

EXHIBIT C 
 Form of
Representative’s Warrant 
 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR
ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING
THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) LAIDLAW & COMPANY (UK) LTD. OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF LAIDLAW & COMPANY (UK)
LTD. OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER. 
 THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO
                     [DATE THAT IS ONE YEAR FROM THE DATE OF THE PROSPECTUS]. VOID AFTER 5:00 P.M., EASTERN TIME,
                     [DATE THAT IS FIVE YEARS FROM THE DATE OF THE PROSPECTUS]. 

COMMON STOCK PURCHASE WARRANT 

For the Purchase of                  Shares of Common Stock

 of 
 VIKING THERAPEUTICS, INC.

 1. Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Laidlaw & Company (UK) Ltd.
(“Holder”), as registered owner of this Purchase Warrant, to Viking Therapeutics, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from
                     [DATE THAT IS ONE YEAR FROM THE DATE OF THE PROSPECTUS] (the “Commencement Date”), and at or before 5:00
p.m., Eastern time,                      [DATE THAT IS FIVE YEARS FROM THE DATE OF THE PROSPECTUS]
(the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to                  shares
[the aggregate of (1) 3% of the number of Firm Shares sold in the Offering, excluding the Option Shares and any shares purchased by Ligand for an aggregate purchase price to the public in excess of $5.0 million and (2) 1.5% of the Firm
Shares purchased by Ligand for an aggregate purchase price to the public in excess of $5.0 million] of common stock of the Company, par value $0.00001 per share (the “Shares”), subject to adjustment as provided in Section 6
hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the
period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $         per Share [125% of the
price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 

 
hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The
term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. 
 2.
Exercise. 
 2.1 Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly
executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased, payable in cash by wire transfer of immediately available funds to an account designated by
the Company or by certified check or official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date, this Purchase Warrant shall become and be void without
further force or effect, and all rights represented hereby shall cease and expire. 
 2.2 Cashless Exercise. If at any time
after the Commencement Date there is no effective registration statement registering, or no current prospectus available for, the resale of the Shares by the Holder, then in lieu of exercising this Purchase Warrant by payment of cash or check
payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to
the Company, together with the exercise form attached hereto, in which event the Company shall issue to Holder Shares in accordance with the following formula: 
  

							
			Y(A-B)		
	X      =		     A		
				
	Where,						
			X		=		The number of Shares to be issued to Holder;
			Y		=		The number of Shares for which this Purchase Warrant is being exercised;
			A		=		The fair market value of one Share; and
			B		=		The Exercise Price.

 For purposes of this Section 2.2, the fair market value of a Share is defined as follows: 

 

	 	(i)	if the Company’s common stock is traded on a national securities exchange, the value shall be deemed to be the closing price on such exchange prior to the exercise form being submitted in connection with the
exercise of this Purchase Warrant; or 

  

	 	(ii)	if the Company’s common stock is actively traded on the over-the-counter market, the value shall be deemed to be the closing bid prior to the exercise form being submitted in connection with the exercise of this
Purchase Warrant; if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Company’s Board of Directors. 

 2.3 Legend. Each certificate for the securities purchased under this Purchase Warrant
shall bear a legend as follows, unless such securities have been registered under the Securities Act of 1933, as amended (the “Securities Act”): 

“The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the
“Securities Act”), or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant to an effective registration statement under the Securities Act, or
pursuant to an exemption from registration under the Securities Act and applicable state law which, in the opinion of counsel to the Company, is available.” 

3. Transfer. 
 3.1 General
Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty
(180) days following the Effective Date to anyone other than: (i) Laidlaw & Company (UK) Ltd. (“Laidlaw”) or an Underwriter or a selected dealer in connection with the sale of shares of the Company’s common
stock pursuant to the terms of that certain Underwriting Agreement, by and between Laidlaw and the other underwriters named on Schedule I thereto (collectively, the “Underwriters”) and the Company, dated as of
            , 2015 (the “Underwriting Agreement”), or (ii) a bona fide officer or partner of Laidlaw or of any such Underwriter or selected dealer, in each case in
accordance with FINRA Conduct Rule 5110(g)(1), or (b) cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(g)(2). On and after 180 days after the Effective Date, transfers to others may be made subject to compliance with or exemptions from
applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly executed and completed, together with this Purchase Warrant and payment of all transfer taxes, if
any, payable in connection therewith. Subject to the other provisions of this Section 3.1, the Company shall within five (5) Business Days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new
Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number as shall be contemplated by any such
assignment. 
 3.2 Restrictions Imposed by the Securities Act. The securities evidenced by this Purchase Warrant shall not be
transferred unless and until: (a) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under the Securities Act and applicable state securities laws,
the availability of which is established to the reasonable satisfaction of the Company (the Company hereby agreeing that the opinion of Sichenzia Ross Friedman Ference LLP shall be deemed satisfactory evidence of the availability of an exemption),
or (b) a registration statement or a post-effective amendment to a registration statement relating to the offer and sale of such securities has been filed by the Company and declared effective by the U.S. Securities and Exchange Commission
(the “Commission”) and compliance with applicable state securities law has been established. 

 4. Registration Rights. 

4.1 Demand Registration. 

4.1.1 Grant of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the
Purchase Warrants and/or the underlying Shares, agrees to register, on one occasion, all or any portion of the Shares underlying this Purchase Warrant (collectively, the “Registrable Securities”). On such occasion, the Company will
file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its commercially reasonable efforts to have the registration statement declared effective
promptly thereafter, subject to compliance with any review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to
which the Holder is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (a) the Holder has elected to participate in the offering covered by such registration statement or (b) if such registration
statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. The demand for
registration may be made at any time during a period of four (4) years beginning on the Commencement Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered
Holders of the Registrable Securities (as listed on the Company’s warrant ledger) within ten (10) days after the date of the receipt of any such Demand Notice. Notwithstanding the foregoing, the Company shall not be required to register
any Registrable Securities pursuant to this Section 4.1.1 that are the subject of a then-effective registration statement. 
 4.1.2
Terms. The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1, but the Holders shall pay any and all underwriting commissions and the expenses of any legal
counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. The Company agrees to use its commercially reasonable efforts to cause the filing required herein to become effective promptly and to
qualify or register the Registrable Securities in such states as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required to register the Registrable Securities in a state in which
such registration would cause: (a) the Company to be obligated to register or license to do business in such state or submit to general service of process in such state, or (b) the principal shareholders of the Company to be obligated to
escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective until the earlier of: (i) the one (1) year
anniversary of the effective date of such registration statement or (ii) the date when all Registrable Securities covered by such registration statement have been sold. The Holders shall only use the prospectuses provided by the Company to sell
the shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission.
Notwithstanding the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section 4.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary
of the effective date of the Registration Statement on Form S-1 (File No. 333-197182), initially filed by the Company with the Commission on July 1, 2014, as amended to date (the “Registration Statement”), in accordance
with FINRA Rule 5110(f)(2)(G)(iv). 

 4.2 “Piggy-Back” Registration. 

4.2.1 Grant of Right. The Holder shall have the right, for a period of no more than seven (7) years from the effective date of the
Registration Statement, in accordance with FINRA Rule 5110(f)(2)(H)(v), to include all or any portion of the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction
contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-4 or Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the
account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock which may be included in the registration statement because, in such underwriter’s
judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion of the Registrable Securities with
respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. To the extent there are multiple holders of Registrable Securities, any exclusion of Registrable Securities shall be made pro-rata among the
holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such holders; provided, however, that the Company shall not exclude any Registrable Securities unless the
Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such registration statement or are not entitled to pro-rata inclusion with the Registrable Securities. Notwithstanding
the foregoing, the Company shall not be required to register any Registrable Securities pursuant to this Section 4.2.1 that are the subject of a then-effective registration statement. 

4.2.2 Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to
Section 4.2.1 hereof, but the Holder shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holder to represent it in connection with the sale of the Registrable Securities. If there is not an
effective registration statement covering all of the Registrable Securities held by the Holder at the time of such a proposed registration, the Company shall furnish the Holder with not less than fifteen (15) days written notice prior to the
proposed date of filing of such registration statement. Notice of such a proposed registration shall continue to be given to the Holder for each registration statement filed by the Company until such time as all of the Registrable Securities held by
the Holder have been sold. The Holder shall exercise the “piggy-back” rights provided for herein by giving written notice within five (5) days of the receipt of the Company’s notice of its intention to file a registration
statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 4.2.2; provided, however, that such registration rights shall
terminate on the seventh anniversary of the effective date of the Registration Statement. 
 4.3 General Terms. 

4.3.1 Indemnification. The Company shall indemnify the Holder of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls the Holder within the meaning of Section 15 of the Securities Act or Section 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), against all
loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the
Securities Act, the Exchange 

 
Act or otherwise, arising from a registration statement registering for resale the Registrable Securities, but only to the same extent and with the same effect as the provisions pursuant to which
the Company has agreed to indemnify the Underwriters contained in Section 5(a) of the Underwriting Agreement. Holder and its successors and assigns, shall severally, and not jointly, indemnify the Company and each person, if any, who controls
the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, each director of the Company, and each officer of the Company who signs the registration statement registering for resale Registrable
Securities, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which the Company may
become subject under the Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of Holder, or its successors or assigns, in writing, for specific inclusion in a registration statement registering for resale
Registrable Securities, to the same extent and with the same effect as the provisions contained in Section 5(b) of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company. 

4.3.2 Exercise of Purchase Warrant. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder to exercise
its Purchase Warrant prior to or after the initial filing of any registration statement or the effectiveness thereof. 
 4.3.3 Documents
to be Delivered by Holder. At least 10 Trading Days prior to the first anticipated filing date of a registration statement registering for resale the Registrable Securities under this Section 4, the Company will notify the Holder of the
information the Company requires from the Holder, if any, which such information shall be delivered to the Company promptly upon request and, in any event, within five Trading Days prior to the applicable anticipated filing date. The Holder further
agrees that it shall not be entitled to be named as a selling security holder in a registration statement filed under this Section 4 or use the related prospectus for offers and resales of Registrable Securities at any time, unless such Holder
has returned to the Company a response to any requests for information as described in the previous sentence. If the Holder returns a request for information after its deadline, the Company shall use its commercially reasonable efforts to take such
actions as are required to name such Holder as a selling security holder in the registration statement or any pre-effective or post-effective amendment thereto and to include (to the extent not theretofore included) in the registration statement the
Registrable Securities identified in such late request for information. The Holder acknowledges and agrees that the information in any request for information as described in this Section 4.3.3 will be used by the Company in the preparation of
the registration statement registering for resale the Registrable Securities and hereby consents to the inclusion of such information in such registration statement. 

5. New Purchase Warrants to be Issued. 

5.1 Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or
assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any
Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the name of the Holder
evidencing the right of the Holder to purchase the number of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned. 

 5.2 Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the
loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase
Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company. 

6. Adjustments. 
 6.1 Adjustments to
Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying this Purchase Warrant shall be subject to adjustment from time to time as hereinafter set forth: 

6.1.1 Share Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of
outstanding shares of common stock of the Company is increased by a stock dividend payable in shares of common stock of the Company or by a split up of shares of common stock of the Company or other similar event, then, on the effective date
thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding shares of common stock of the Company, and the Exercise Price shall be proportionately decreased. 

6.1.2 Aggregation of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of
outstanding shares of common stock of the Company is decreased by a consolidation, combination or reclassification of shares of common stock of the Company or other similar event, then, on the effective date thereof, the number of Shares purchasable
hereunder shall be decreased in proportion to such decrease in outstanding shares of common stock of the Company, and the Exercise Price shall be proportionately increased. 

6.1.3 Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares
of common stock of the Company other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of the shares of common stock of the Company, or in the case of any share reconstruction or amalgamation or
consolidation of the Company with or into another corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation and which does not result in any reclassification or reorganization
of the outstanding shares of common stock of the Company), or in the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the Company
is dissolved, the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder
immediately prior to such event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation, or consolidation, or upon a
dissolution following any such sale or transfer, by a holder of the number of shares of common stock of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a
change in the outstanding shares of common stock of the Company covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to 

 
Section 6.1.1, Section 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations, share
reconstructions or amalgamations, or consolidations, sales or other transfers. 
 6.1.4 Changes in Form of Purchase Warrant. This
form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in this Purchase
Warrant. The acceptance by Holder of the issuance of new Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the computation thereof. 

6.2 Substitute Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the
Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change of the outstanding shares of common stock of the Company), the corporation formed
by such consolidation or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the Holder shall have the right thereafter (until the stated expiration of this Purchase Warrant) to
receive, upon exercise of this Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation or share reconstruction or amalgamation, by a holder of the number of shares of common stock
of the Company for which this Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments which shall be
identical to the adjustments provided for in this Section 6. The above provision of this Section 6 shall similarly apply to successive consolidations or share reconstructions or amalgamations. 

6.3 Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Shares upon
the exercise of this Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down,
as the case may be, to the nearest whole number of Shares or other securities, properties or rights. 
 6.4 Notice of Change in Exercise
Price. Upon the occurrence of each adjustment to the Exercise Price pursuant to this Section 6, the Company at its expense will promptly compute such adjustment, in good faith, in accordance with the terms of this Purchase Warrant, and
prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Shares or other securities issuable upon exercise of this Purchase Warrant (as applicable), describing the
transactions giving rise to such adjustments and showing in reasonable detail the facts upon which such adjustments are based. The Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 7. Reservation and Listing. The Company shall at all times reserve and keep available out of its authorized shares of common stock, solely for the
purpose of issuance upon exercise of this Purchase Warrant, such number of shares of common stock or other securities, properties or rights as shall be issuable upon the exercise hereof. The Company covenants and agrees that, upon exercise of this
Purchase Warrant and payment of the Exercise Price, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights
of any 

 
shareholder. As long as this Purchase Warrant shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Shares issuable upon exercise of this Purchase Warrant
to be listed (subject to official notice of issuance) on all national securities exchanges (or, if applicable, on the OTCQB or higher platform of the OTC Markets, Inc. or any successor trading market) on which the Shares issued to the public in the
Offering may then be listed and/or quoted. 
 8. Certain Notice Requirements. 

8.1 Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holder the right to vote or consent
or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company. If, however, at any time prior to the expiration of this Purchase Warrant and its exercise,
any of the events described in Section 8.2 shall occur, then, in the case of the occurrence of one or more of said events, the Company shall give written notice of such event at least ten days prior to the date fixed as a record date or the
date of closing the transfer books for the determination of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding
up or sale; provided that, the Company shall not be required to provide such notice if such notice and the contents thereof shall be deemed to constitute material non-public information. Such notice shall specify such record date or the date
of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. 

8.2 Events Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon the occurrence of
one or more of the following events: (a) if the Company shall take a record of the holders of its outstanding shares of common stock for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a
cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (b) the Company shall offer to all the holders of its
outstanding shares of common stock any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (c) a
dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business shall be proposed. 

 8.3 Transmittal of Notices. All notices, requests, consents and other communications under
this Purchase Warrant shall be in writing and shall be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (a) if to the registered Holder of this Purchase Warrant, to the address of the
Holder as shown on the books of the Company, or (b) if to the Company, to the following address or to such other address as the Company may designate by notice to the Holder: 

If to the Holder: 

Laidlaw & Company (UK) Ltd. 

546 Fifth Avenue, 5th Floor 

New York, New York 10036 
 Attn:
Attention: Hugh Regan, Executive Director 
 Fax No.: (212) 297-0670 

with a copy (which shall not constitute notice) to: 

Sichenzia Ross Friedman Ference LLP 

61 Broadway, 32nd Floor 

New York, NY 10022 
 Attn: Richard
A. Friedman, Esq. 
 Fax No.: 212-930-9725 

If to the Company: 
 Viking
Therapeutics, Inc. 
 11119 North Torrey Pines Road, Suite 50 

San Diego, CA 92037 
 Attention:
Brian Lian, Ph.D., President and Chief Executive Officer 
 with a copy (which shall not constitute notice) to: 

Paul Hastings LLP 
 1117 S.
California Avenue 
 Palo Alto, CA 94304 

Attention: Jeffrey T. Hartlin, Esq. 

Fax No: 650-320-1904 
 9. Miscellaneous.

 9.1 Amendments. The Company and Laidlaw may from time to time supplement or amend this Purchase Warrant without the approval of
the Holder in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or questions arising
hereunder that the Company and Laidlaw may deem necessary or desirable and that the Company and Laidlaw deem shall not adversely affect the interest of the Holder. All other modifications or amendments shall require the written consent of and be
signed by the party against whom enforcement of the modification or amendment is sought. 
 9.2 Headings. The headings contained
herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant. 

 9.3. Entire Agreement. This Purchase Warrant (together with the other agreements and
documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the
parties, oral and written, with respect to the subject matter hereof. 
 9.4 Binding Effect. This Purchase Warrant shall inure solely
to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained. 
 9.5 Governing Law;
Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company
hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to, this Purchase Warrant shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court
for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.
Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8.3 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the
other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on
behalf of its shareholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Purchase Warrant or
the transactions contemplated hereby. 
 9.6 Waiver, etc. The failure of the Company or the Holder to at any time enforce any of the
provisions of this Purchase Warrant shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right of the Company or the Holder to thereafter
enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party
or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or
non-fulfillment. 
 9.7 Execution in Counterparts. This Purchase Warrant may be executed in one or more counterparts, and by the
different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed
by each of the parties hereto and delivered to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission. 

 9.8 Exchange Agreement. As a condition of the Holder’s receipt and acceptance of this
Purchase Warrant, Holder agrees that, at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Laidlaw enter into an agreement (the “Exchange Agreement”) pursuant to which they agree that
this Purchase Warrant will be exchanged for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly
authorized officer as of the      day of             , 2015. 
  

							
			VIKING THERAPEUTICS, INC.
			
			By:		  

					Name:		Brian Lian, Ph.D.
					Title:		President and Chief Executive Officer

 [Form to be used to exercise Purchase Warrant] 

Date:             , 20     

The undersigned hereby elects irrevocably to exercise the Purchase Warrant for
                 shares of common stock, par value $0.00001 per share (the “Shares”), of Viking Therapeutics, Inc., a Delaware corporation (the
“Company”), and hereby makes payment of $         (at the rate of $         per Share) in payment of the Exercise Price pursuant thereto. Please issue
the Shares as to which the Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which the Purchase Warrant has not been exercised. 

or 

The undersigned hereby elects irrevocably to convert its right to purchase
                 shares of common stock of the Company under the Purchase Warrant for
                 Shares, as determined in accordance with the following formula: 

 

							
							   Y(A-B)   
		X		=		        A
				
	Where,						
			   X		=		The number of Shares to be issued to Holder;
			   Y		=		The number of Shares for which the Purchase Warrant is being exercised;
			   A		=		The fair market value of one Share is equal to $        ; and
			   B		=		The Exercise Price which is equal to $         per share

 The undersigned agrees and acknowledges that the calculation set forth above is subject
to confirmation by the Company and any disagreement with respect to the calculation shall be resolved by the Company in its sole discretion. 

Please issue the Shares as to which the Purchase Warrant is exercised in accordance with the instructions given below and, if
applicable, a new Purchase Warrant representing the number of Shares for which the Purchase Warrant has not been converted. 
  

					
			Signature		  

					
			
			Signature Guaranteed		  

 INSTRUCTIONS FOR REGISTRATION OF SECURITIES 

 

			
	Name:		  

			(Print in Block Letters)
		
	Address:		  

		
			  

		
			  

 NOTICE: The signature to this form must correspond with the name as written upon the face of the Purchase
Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange. 

 [Form to be used to assign Purchase Warrant] 

ASSIGNMENT 
 (To be executed by the registered Holder to effect
a transfer of the within Purchase Warrant): 
 FOR VALUE RECEIVED,
                     does hereby sell, assign and transfer unto
                     the right to purchase the shares of common stock, par value $0.00001 per share, of Viking Therapeutics, Inc., a Delaware
corporation (the “Company”), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company. 

Dated:             , 20     

 

			
	Signature		  

			
		
	Signature Guaranteed		  

 NOTICE: The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant
without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange.EX-10.29

 Exhibit 10.29 

*** Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) 

and 240.24b-2 
 RESEARCH SERVICES
AGREEMENT 
 THIS RESEARCH SERVICES AGREEMENT (the “Agreement”) is made effective as of 27 January , 2015 (the “Effective
Date”), by and between Viking Therapeutics, Inc., a Delaware corporation located at 11119 North Torrey Pines Road, Suite 50, La Jolla, CA 92037, USA (“Viking”) and Academisch Medisch Centrum, with registered office at
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands (“Institution”). 
 Viking and Institution, also individually a “party”
and jointly the “parties”) 
 WHEREAS 
 (A)
Viking wishes to engage Institution to conduct, and Institution wishes to perform for Viking, a series of one or more project(s) involving proprietary materials and confidential information of Viking and/or Institution, all on the terms and
conditions set forth herein; 
 (B) Viking understands that one of Institution’s primary missions is education, scientific research and the
advancement of knowledge and the research under this Agreement will be designed to carry out that mission. The manner of performance of the research by Institution shall be determined solely by the Principal Investigator (as defined below).
Institution does not guarantee specific results. 
 (C) Viking understands that Institution may be involved in similar research as the research
contemplated hereunder on behalf of itself or others. Institution shall be free to continue such research provided that it is compliant with any obligations and restrictions pursuant to this Agreement (which could mean that it is conducted
separately and by different investigators from the research) and Viking shall not gain any rights via this Agreement to other research. 
 (D)
Institution does not guarantee that any intellectual property will result from the Research, that any resulting intellectual property will be free of dominance by other’ rights, including rights based on inventions made by other inventors
within Institution independently of the Research. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below,
and for other good and valuable consideration, the receipt of which is hereby acknowledged, Viking and Institution hereby agree as follows: 
 1.
Services; SOWs. 
 (a) Parties may from time to time agree on a statement of work (an “SOW”) substantially
in the form attached to this Agreement as Exhibit A. Each SOW will, upon execution by both parties, form a part of this Agreement and will be subject to all of the terms and conditions contained herein, except to the extent otherwise expressly set
forth in such SOW. 

  
 1 

 (b) Institution will use reasonable efforts to perform the research and services set forth
and under the direction of a Principal Investigator as identified in each SOW (such research and services, the “Services”) in a timely, professional and workmanlike manner in accordance with the applicable academic standards, and in
strict accordance with the terms of this Agreement and the SOW (including any timetable and any regulatory standard(s) set forth therein and the Manufacturing Rider to the extent applicable to the SOW) and in strict accordance with all applicable
laws and regulations. In performing the Services, Institution agrees to provide its own personnel, equipment, tools and other materials at its own expense, except as expressly specified otherwise in an SOW. If any services, functions or
responsibilities not specifically described in this Agreement or an SOW are required for the proper performance and provision of the Services, the parties will in good faith discuss whether these additional services, functions or responsibilities
will be part of the SOW and/or whether Viking will pay Institution any additional consideration for the performance thereof. The Services will include a draft report of the results of all studies performed pursuant to the Services, and a final
report after Viking’s review of the draft. For Services that include the manufacture of any compound or substance to specifications, the rider of manufacturing terms set forth in Exhibit B (“Manufacturing Rider”) will apply.
The SOW for such manufacturing Services will incorporate the Manufacturing Rider by reference, and state to what portion of the Services the Manufacturing Rider applies. 

(c) To enable Institution to perform the Services, as expressly specified in an SOW, Viking may provide Viking Materials in accordance
with Section 3 and may disclose Viking’s Confidential Information protected in accordance with Section 4. Institution will be excused from performing its obligations on the timing specified in this Agreement or the applicable SOW to
the extent that Viking’s failure to perform materially prevents Institution from doing so, calculated on a day for day basis. In addition, Institution will be excused from its failure perform to the extent that Viking’s failure to perform
materially prevents Institution from performing. In any event, each party will promptly notify the other party of any delay or other failure and the consequences of the same and parties shall use commercially reasonable efforts and cooperate with
each other to overcome or mitigate the same. 
 (d) No SOW may alter or amend the terms set forth in this Agreement unless it
explicitly references the Section of this Agreement that does not apply and states the variance from such Section or alternate provision that does apply, with regard to the particular Services covered by such SOW. This same principle applies with
regard to the Manufacturing Rider and the terms of the Manufacturing Rider may only be varied by the same procedure as provided in the foregoing sentence. 

(e) Viking may at any time request, in writing, that the scope of Services provided under this Agreement and any SOW be changed. As
soon as reasonably possible upon receiving such request, Institution will deliver to Viking in writing an evaluation of the request; such evaluation will describe and support the increase or decrease in Institution’s actual costs, if any,
expected to reasonably result from such requested changes, and the amount of additional time, if any, reasonably required and necessary to implement such requested changes. The parties will negotiate in good faith to mutually agree to make any
reasonable adjustments to: (i) the compensation payable under this Agreement and any applicable SOW based on the amount of any increase or decrease in Institution’s actual costs and (ii) the delivery schedule or timeline for the
Services and/or SOW, in each case, that is reasonably required and necessary to implement such requested changes; provided that the Institution will use commercially reasonable efforts and cooperate to avoid or, if not possible, minimize any delay
and/or additional costs. For the avoidance of doubt, Institution will not proceed with the requested changes unless and until it receives written instructions to do so from Viking. 

  
 2 

 (f) Institution agrees during the term of this Agreement not to accept work or enter into
any agreement or accept any obligation that is inconsistent or incompatible with Institution’s obligations under this Agreement or any SOW or the scope of Services rendered for Viking. Institution represents and warrants that, to the best of
its knowledge, there is no other existing agreement or duty on Institution’s part inconsistent with this Agreement. 
 2. Payment. As full
compensation for any Services performed by Institution under an SOW, Viking will pay to Institution a total amount not to exceed the maximum amount set forth in the applicable SOW. Unless other terms are expressly set forth in the applicable SOW,
Viking will pay Institution any amounts for Services within thirty (30) days following the date of Institution’s invoice, which will be issued no earlier than the date an event or a milestone specified in the SOW is completed and the
applicable Services are accepted by Viking in accordance with this Agreement. Upon termination of this Agreement (other than for Institution’s material breach), Institution will be paid fees on a proportional basis for Services performed and
accepted by Viking in accordance with this Agreement and any applicable SOW, up to and including the effective date of such termination. 
 3. Viking
Materials. Viking will provide to Institution any materials described in the applicable SOW (together with all derivatives of, analogs of, intermediates of, progeny of, portions of, improvements to, and other materials incorporating or that
could not be made without using such materials, the “Viking Materials”). Institution will use the Viking Materials solely for the purpose of performing the Services and in compliance with all applicable laws and regulations.
Institution will not use the Viking Materials for any other purpose, or other than as permitted under the applicable SOW. Viking will own all right, title and interest in and to the Viking Materials. Without limitation to its obligations under
Section 4, (i) Institution will not sell, transfer, disclose or otherwise provide access to the Viking Materials, any method or process relating thereto, or any information regarding the Viking Materials to any person or entity without the
prior express written consent of Viking and (ii) Institution may allow access to the Viking Materials to its employees and agents for purposes consistent with this Agreement, provided that such employees and agents are bound by written
agreement to use the Viking Materials in a manner that is consistent with the terms of this Agreement to perform the Services. When the Services are completed, Institution will return any remaining quantities of the Viking Materials to Viking, or
otherwise dispose of the Viking Materials as directed by Viking in writing. INSTITUTION ACKNOWLEDGES AND AGREES THAT THE VIKING MATERIALS MAY HAVE BIOLOGICAL AND/OR CHEMICAL PROPERTIES THAT ARE UNPREDICTABLE AND UNKNOWN AT THE TIME OF TRANSFER, THAT
THEY ARE TO BE USED WITH CAUTION AND PRUDENCE, AND ARE NOT TO BE USED FOR TESTING IN OR TREATMENT OF HUMANS. 
 4. Confidential Information. Any and
all information and material, including formulas, data, inventions, know-how, practices, processes, business, technical and financial information, disclosed or made disclosed by the disclosing party (the “Disclosing Party”) to the
receiving party (the “Receiving Party”) or obtained by the Receiving Party through inspection or observation of the Disclosing Party’s premises or facilities (whether in writing, or in oral, graphic, electronic or any other
form) that is marked as (or provided under circumstances reasonably indicating it is) 

  
 3 

 
confidential or proprietary, or if disclosed orally or in other intangible form or in any form that is not so marked, that is identified as confidential at the time of such disclosure is referred
to herein as “Confidential Information.” Without limitation to the foregoing, Institution expressly agrees that all Viking Results (as defined in Section 6) will be deemed Viking’s Confidential Information without any need
for further marking or designation. The Receiving Party’s use of the Disclosing Party’s Confidential Information will be limited to the following purpose (as applicable to that party) (the “Purpose”): (i) Institution
will not use Viking’s Confidential Information except for the sole purpose of carrying out its obligations as expressly set forth under this Agreement or any SOW; and (ii) Viking will not use Institution’s Confidential Information
except for the purpose of carrying out its obligations or exercising its rights under this Agreement or any SOW. The Receiving Party agrees that it will (A) hold the Disclosing Party’s Confidential Information in trust and confidence;
(B) not use the Disclosing Party’s Confidential Information in any manner or for any purpose other than the Purpose; (C) reproduce the Disclosing Party’s Confidential Information only to the extent reasonably required for the
Purpose, and (D) not disclose, deliver, provide, disseminate or otherwise make available to any third party, directly or indirectly, any of the Disclosing Party’s Confidential Information without first obtaining the Disclosing Party’s
express written consent on a case-by-case basis. The Receiving Party may disclose the Disclosing Party’s Confidential Information only to employees and agents of the Receiving Party who have a need to know such Confidential Information for
carrying out the Purpose, and who are each obligated by a written agreement to comply with confidentiality provisions that are comparable to and no less restrictive than those set forth in this Agreement. The Receiving Party will take at least the
same degree of care that it uses to protect its own confidential and proprietary information of similar nature and importance (but in no event less than reasonable care) to protect the confidentiality and avoid the unauthorized use, disclosure,
publication or dissemination of the Disclosing Party’s Confidential Information. These obligations of confidentiality and non-use will survive, and remain in effect for a period of five (5) years from, the expiration or termination of this
Agreement. The nondisclosure and nonuse obligations in this Section 4 will not apply to any Confidential Information to the extent that the Receiving Party can establish by competent written proof that such Confidential Information of the
Disclosing Party (a) is or has become generally known or available other than by any act or omission of the Receiving Party; (b) was rightfully known by the Receiving Party prior to the time of first disclosure to the Receiving Party,
(c) is independently developed by the Receiving Party without the use of the Disclosing Party’s Confidential Information; or (d) is rightfully obtained without restriction from a third party who has the right to make such disclosure
and without breach of any duty of confidentiality to the Disclosing Party. In addition, the Receiving Party may use or disclose the Disclosing Party’s Confidential Information to the extent (1) specifically approved in advance in writing
by the Disclosing Party or (2) that the Receiving Party is legally compelled to disclose any of the Disclosing Party’s Confidential Information provided that, in the case of (2), the Receiving Party will use reasonable efforts to give
advance notice of such compelled disclosure to the Disclosing Party, will cooperate with the Disclosing Party in connection with any efforts to prevent or limit the scope of such disclosure and/or use of the Disclosing Party’s Confidential
Information, including making a reasonable effort to obtain a protective order requiring that such Confidential Information be used only for the purposes for which the law or regulation required, and will use and disclose such Confidential
Information solely to the extent required by the law or regulation. 

  
 4 

 5. DISCLAIMER OF WARRANTIES.  

5.1 VIKING MAKES NO AND HEREBY DISCLAIMS ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO ANY
MATERIALS AND CONFIDENTIAL INFORMATION, INCLUDING ANY REPRESENTATION OR WARRANTY OF TITLE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THEY ARE FREE FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE.
VIKING MAKES NO REPRESENTATIONS THAT THE USE OF THE MATERIALS OR VIKING’S CONFIDENTIAL INFORMATION WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTIES. 

5.2 Institution assumes no responsibility or liability for the nature, conduct or results of any research, testing or other work performed hereunder. All
Results conceived, developed and/or reduced to practice by Institution, Principal Investigator, or any of Institution’s employees, consultants, appointees or agents, during and directly arising from the research under this Agreement or any
particular SOW are made available to Viking “as is” and Viking understands and agrees that such results are experimental in nature and are made available without any representation or warranty as is set out in this Clause 5. 

5.3 INSTITUTION MAKES NO AND HEREBY DISCLAIMS ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT
TO ANY CONFIDENTIAL INFORMATION AND ANY RESULTS CONCEIVED, DEVELOPED AND/OR REDUCED TO PRACTICE BY INSTITUTION, PRINCIPAL INVESTIGATOR, OR ANY OF INSTITUTION’S EMPLOYEES, CONSULTANTS, APPOINTEES OR AGENTS, DURING AND DIRECTLY ARISING FROM THE
RESEARCH UNDER THIS AGREEMENT OR A PARTICULAR SOW, INCLUDING ANY REPRESENTATION OR WARRANTY OF TITLE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THEY ARE FREE FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE
LIKE. INSTITUTION MAKES NO REPRESENTATIONS THAT THE USE OF THE RESULTS AS IN THIS CLAUSE 5.3 INDICATED OR INSTITUTION’S CONFIDENTIAL INFORMATION WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTIES. 

6. Results of Services. Institution will keep complete, accurate and authentic accounts, notes, data and records of the Services and the results of
these Services, in sufficient detail for patent application purposes. Institution will promptly and fully disclose to Viking any and all Viking Results. Such disclosure will include copies of relevant summaries and reports. “Viking
Results” will mean all discoveries, ideas, methodologies, know-how, trade secrets, formulas, concepts, information, data, results, technology, specifications, inventions and other creations (whether or not patentable) that are conceived,
created, developed or otherwise provided by or for Institution (alone or with others) or reduced to practice in the course of performing, or are obtained from, based on, result from or in connection with, the Services, after the execution of this
Agreement (and, if based on Viking’s Confidential Information, after termination of this Agreement) and whether or not conceived of, created or otherwise developed during regular business hours, including any of the foregoing based on or
relating to the Viking Materials or Viking’s Confidential Information, the manufacture, use and/or testing of any of the Viking Materials or Viking’s Confidential Information, and any feedback, improvements or modifications to or
derivatives of any of the foregoing, together with all intellectual property and proprietary rights therein (including patent applications and patents claiming the same). Viking Results will also include all derivatives of, analogs of, intermediates
of, progeny of, portions of, improvements to, and other materials incorporating or that could not be made without using, any Viking Materials. 

  
 5 

 7. Institution Representations and Warranties. 

(a) Institution represents, warrants and covenants that: (i) Institution has the full power and authority to enter into this
Agreement and the SOWs and to perform its obligations hereunder and there under, without the need for any consents, approvals or immunities not yet obtained; (ii) Institution’s execution of and performance under this Agreement and the SOWs
will not breach any oral or written agreement with any third party or any obligation owed by Institution to any third party to keep any information or materials in confidence or in trust; (iii) the Viking Results will be the original work of
Institution, and any persons involved in the development of Viking Results have executed (or prior to any such involvement, will execute) a written agreement with Institution in which such persons (A) assign to Institution all right, title and
interest in and to the Viking Results in order that Institution may fully grant the rights to Viking as provided herein and (B) agree to be bound by confidentiality and non-disclosure obligations no less restrictive than those set forth in this
Agreement; (iv) Institution has the right to grant the rights and assignments granted herein, without the need for any assignments, releases, consents, approvals, immunities or other rights not yet obtained; 

(b) If Institution breaches any of the warranties in Section 7(a), in addition to and not in lieu or limitation of any other
rights or remedies Viking may have, Viking will be entitled, at its sole option and discretion, (i) to a full refund of amounts paid in respect of the defective Service or Viking Results or (ii) require Institution to re-perform any
Services not conforming to the foregoing warranties or repair or correct any Viking Results not conforming to the foregoing warranties at Institution’s sole cost and expense within a period of time to be specified by Viking in Viking’s
reasonable discretion. 
 (c) The express undertakings and warranties given by Institution in this Agreement are in lieu of all other
warranties, conditions, terms, undertakings and obligations, whether express or implied by statute, common law, custom, trade usage, course of dealing or in any other way. All of these are excluded to the fullest extent permitted by law. 

8. Proprietary Rights; Licenses. 

(a) Viking will solely own all right, title and interest in and to the Viking Results. Accordingly, except for Institution’s rights
in any technology, inventions, discoveries, works of authorship or other prior creations that were conceived, created or reduced to practice by or for Institution (alone or with others) prior to the Effective Date (collectively, “Institution
Background Technology”), Institution hereby irrevocably assigns to Viking all of Institution’s right, title and interest in and to the Viking Results, effective immediately upon the inception, conception, creation or development
thereof. Institution retains no rights to use the Viking Results and agrees not to challenge the validity of Viking’s ownership in the Viking Results, except as may be expressly set forth in the applicable SOW or otherwise agreed in writing by
the parties and with the exception that notwithstanding any provision to the contrary in this Agreement or any particular SOW. 

  
 6 

 (b) To the extent, if any, that any Viking Results are not assignable or that Institution
retains any right, title or interest in and to any Viking Results, Institution (i) unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind against Viking with respect to such
rights; (ii) agrees, at Viking’s request and expense, to consent to and join in any action to enforce such rights; and (iii) hereby grants to Viking a perpetual, irrevocable, fully paid-up, royalty-free, transferable, sub licensable
(through multiple levels of sub licensees), exclusive, worldwide right and license to use, reproduce, distribute, display and perform (whether publicly or otherwise), prepare derivative works of and otherwise modify, make, sell, offer to sell,
import and otherwise use and exploit (and have others exercise such rights on behalf of Viking) all or any portion of such Viking Results, in any form or media (now known or later developed). The foregoing license includes the right to make any
modifications to such Viking Results regardless of the effect of such modifications on the integrity of such Viking Results, and to identify Institution, as one or more authors of or contributors to such Viking Results or any portion thereof,
whether or not such Viking Results or any portion thereof have been modified. Institution further irrevocably waives any “moral rights” or other rights with respect to attribution of authorship or integrity of such Viking Results that
Institution may have under any applicable law under any legal theory. 
 (c) Institution will, and will cause its employees
performing hereunder to, take all steps and execute and deliver all documents reasonably necessary to evidence or record such assignment by Viking, or to perfect or enforce the Viking Results. Institution hereby appoints Viking as Institution’s
attorney-in-fact for the purpose of executing and delivering such documents if Viking is unable, after making reasonable inquiry, to obtain such from Institution. If Institution enjoys a similar appointment from its employees, it will exercise it
with respect to the Viking Results in the manner and to the extent requested by Viking. Institution will provide the assistance as called for in this paragraph both during and after the term of this Agreement for no additional consideration.
Institution will only use employees (or consultants or other agents of Institution) in the performance of the Services that are under a written obligation to assign the Results to Institution. In performing the Services, Institution will only use
technology (whether in the form of know-how, patented or otherwise) that Institution has a legal right to use. Institution agrees and acknowledges that Institution will acquire no rights of any kind whatsoever (including by ownership, license,
option or otherwise) with respect to any Viking Materials, any of Viking’s Confidential Information or any other of Viking’s information or materials, or any intellectual property or proprietary rights therein, as a result of
Institution’s performance under this Agreement (unless otherwise set out therein) or otherwise. 
 9. Term. This Agreement will commence on the
Effective Date and will, unless earlier terminated by either party in accordance with Section 10, continue in full force and effect for a period being the longer of; (i) one (1) year; and (ii) the end date stated in the last SOW
executed under this Agreement. 
 10. Termination. 

(a) Viking may terminate this Agreement or any SOW at its convenience, with or without cause, upon thirty (30) days’ prior
written notice to Institution. For the avoidance of doubt, termination of any SOW will not itself terminate any other SOW, and such remaining SOW(s) will remain in full force and effect until the completion of the Services in accordance with the
terms there under or terminated in accordance with this Section 11(a) or Section 11(b), as applicable. 

  
 7 

 (b) Either party may terminate this Agreement and/or any SOW for the other’s
party’s material breach of this Agreement or any SOW that is not cured within thirty (30) days following notice from the non-breaching party to the breaching party specifying such breach. Any such termination will be effective at the end
of such thirty (30) days. Viking may also terminate this Agreement immediately for Institution’s breach of Sections 4 and 9. 

(c) Upon the effective date of any termination of this Agreement or any SOW, Institution will immediately cease performing any Services
under this Agreement or such SOW, as applicable. Providing that Viking has otherwise performed its material obligations under this Agreement, within 45 days after any termination by Viking, Institution will provide a final written report to Viking
detailing the Viking Results and the Services performed through the effective date of termination. Unless this Agreement has been terminated by Viking for material breach by Institution, Viking agrees to pay Institution; (i) any amounts due for
Services actually rendered in accordance with this Agreement and any applicable SOW; and (ii) any non-cancellable and unrecoverable obligations committed before receipt of the notice of termination, provided that Institute provides Viking with
satisfactory proof that such expenses cannot be cancelled or recovered, and such amounts will be in full satisfaction of any obligation or liability of Viking to Institution for payments due to Institution under this Agreement. Sections 3, 4, 5, 6,
8, 9, 11, 12, 13 and 14 will survive the expiration or termination of this Agreement. Termination of this Agreement by either party will not act as a waiver of any breach of this Agreement or any SOW and will not act as a release of either party
from any liability for breach of such party’s obligations under this Agreement or any SOW. Neither party will be liable to the other for damages of any kind solely as a result of terminating this Agreement in accordance with its terms, and
termination of this Agreement by a party will be without prejudice to any other right or remedy of such party under this Agreement or applicable law and regulations. 

(d) Upon any termination of this Agreement or at any time upon Viking’s request and at Viking’s sole option, Institution will
promptly return to Viking or otherwise dispose of any and all Viking Material and/or Viking’s Confidential Information. Upon any termination and providing that Viking has otherwise performed its material obligations under this Agreement,
Institution will also promptly deliver all Viking Results then in progress, and all Viking Materials and other information or materials provided by or on behalf of Viking under this Agreement or any SOW. Subject to the foregoing, upon any
termination of this Agreement, Viking will promptly return to Institution any and all of Institution’s Confidential Information and other information or materials provided by or on behalf of Institution under this Agreement or any SOW. 

11. Independent Contractors. 

(a) The parties will perform their obligations under this Agreement as independent Institutions and nothing contained in this Agreement
will be construed to be inconsistent with such relationship or status. This Agreement will not constitute, create or in any way be interpreted as a joint venture or partnership of any kind, nor to render Institution to be Viking’s agent.
Institution is not authorized and will not have any right, power or authority of any kind to make any representation, contract or commitment, or to assume, create or incur any expense, liability or obligation, express or implied, on behalf of
Viking, or otherwise bind Viking in any respect whatsoever. 

  
 8 

 (b) Further, it is not the intention of this Agreement or any of the SOWs or of the
parties hereto to confer a third party beneficiary right of action upon any third party or entity whatsoever, and nothing in this Agreement or any of the SOWs will be construed to confer upon any third party other than the parties hereto a right of
action under this Agreement or any SOW or in any manner whatsoever. 
 (c) Institution (and its employees and agents) will not be
entitled to any of the benefits Viking may make available to its employees, such as group insurance, profit-sharing or retirement benefits. 

(d) All amounts payable to Institution under this Agreement will be paid in Euro’s and are exclusive of VAT (or any similar tax).
Viking may regularly report amounts paid to Institution with the Internal Revenue Service as required by law. Because Institution is an independent contractor, Viking will not withhold or make payments for social security, make unemployment
insurance or disability insurance contributions, or obtain worker’s compensation insurance on Institution’s (or its employees’ or agents’) behalf. 

12. Indemnification. 
 (a)
Indemnification of Viking. In addition to any other remedy available to Viking, Institution shall defend, indemnify and hold harmless Viking, its Affiliates and its and their respective officers, directors, partners, shareholders,
employees and agents from and against any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties and reasonable lawyers’ fees and disbursement (“Losses”), incurred by
them to the extent resulting from or arising out of or in connection with (a) any breach of any obligation in this Agreement by Institution, the Principal Investigator or Institution’s researchers involved in the research under this
Agreement, (b) the inaccuracy or breach of any representation or warranty made by Institution in this Agreement or (c) the enforcement of Viking’s rights under this Section 13, except to the extent such Losses arise as a result
of the negligence, fraud, willful misconduct or wrongful act of Viking, its Affiliates or its or their respective officers, directors, partners, shareholders, employees or agents. 

(b) Indemnification of Institution. In addition to any other remedy available to Institution, Viking shall defend, indemnify and
hold harmless Institution, its Affiliates and its and their respective officers, directors, partners, shareholders, employees and agents from and against any and all Losses incurred by them to the extent resulting from or arising out of or in
connection with (a) any breach of any obligation in this Agreement by Viking, (b) the inaccuracy or breach of any representation or warranty made by Viking in this Agreement, (c) any material damages or personal injury or death
suffered as a result of the use by Viking or its Affiliates of the Results, or (d) the enforcement of Institution’s rights under this Section 13, except to the extent such Losses arise as a result of the negligence, fraud, willful
misconduct or wrongful act of Institution, its Affiliates or its or their respective officers, directors, partners, shareholders, employees or agents. 

13. Limitation of Liability. 
 (a)
The total aggregate liability of Institution under this Agreement, including for any liability under the indemnity provided in Clause 11.1, shall be limited to the maximum amount paid to Institution by Viking under the Research Budget pursuant
to Clause 3 at the moment any such liability occurs. 

  
 9 

 (b) Consequential Loss In no event shall the indemnifying party under Clause 13 be
liable to the other party for special, incidental or consequential damages arising under or as a result of this Agreement (or termination thereof), including, but not limited to, the loss of prospective profits or on account of expenses,
investments, or commitments in connection with the business or goodwill or otherwise. 
 14. Entire Agreement. This Agreement, together with the
Exhibits attached hereto and any SOWS, which are incorporated herein by reference, sets forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the parties with respect to its subject matter,
and supersedes and terminates all prior agreements, covenants, promises, agreements, warranties, representations, conditions, and understandings, whether written or oral, between the parties with respect to such subject matter, and all past courses
of dealing or industry custom. This Agreement may only be amended by a writing signed by the respective authorized officers of the parties hereto. In the event there is a conflict between an SOW and this Agreement, the terms of this Agreement shall
govern. 
 15. Governing Law; Venue. This Agreement is to be construed in accordance with and governed by the laws of the State of California (as
permitted by Section 1646.5 of the California Civil Code or any similar successor provision) excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the
substantive law of another jurisdiction without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of California to the rights and duties of the parties.
Any legal suit, action or proceeding arising out of or relating to this Agreement will be commenced in a federal court in the Southern District of California or in state court in the County of San Diego, California, and each party hereto irrevocably
submits to the exclusive jurisdiction and venue of any such court in any such suit, action or proceeding. 
 16. Noninterference. Each party
acknowledges that the other party’s relationships with its employees, agents, suppliers, customers and vendors are valuable business assets. Accordingly, each party agrees that, during the period of this Agreement and for one (1) year
thereafter, such party shall not (for itself or for any third party) divert or attempt to divert from the other party any business, employee, agent, supplier, client, customer or vendor, through solicitation or otherwise. 

17. Severability. If for any reason a court of competent jurisdiction finds any provision of this Agreement, or portion thereof, to be void, invalid or
unenforceable, that provision will be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this Agreement will continue in full force and effect. 

18. Assignment. Institution acknowledges that Viking has entered into this Agreement on the basis of the particular abilities of Institution.
Accordingly, Institution will not and will not have the right to assign, this Agreement or any of its rights or obligations under this Agreement without the prior written consent of Viking, not unreasonably to be withheld. Subject to the foregoing,
this Agreement will be binding upon and will inure to the benefit of the parties and their respective successors and permitted assigns. 

  
 10 

 19. Notices. Any notice, report, communication or consent required or permitted by this Agreement will be
in writing and will be delivered personally or sent (a) by prepaid registered or certified mail, return receipt requested, (b) by overnight express delivery service by an internationally recognized courier, or (c) by email or
facsimile transmission with confirmed answer-back, followed within fourteen (14) days by a copy mailed in the preceding manner, addressed to the other party at the address set forth on the signature page of this Agreement or at such other
address for which such party gives notice hereunder. Notice by personal delivery will be deemed effective upon receipt. Notice by courier or registered mail will be deemed effective three (3) business dates after the date sent. Notice by email
or facsimile will be deemed effective upon sender’s receipt of confirmation of recipient’s receipt of the email or fax. 
 20. Waiver;
Construction. Failure by either party to enforce any provision of this Agreement will not be deemed a waiver of future enforcement of that or any other provision, and no waiver will be effective unless made in writing and signed by the waiving
party. This Agreement has been negotiated by the parties and their respective counsel and will be interpreted fairly in accordance with its terms and without any strict construction in favor of or against either party 

21. Counterparts. This Agreement may be executed (including by facsimile signature) in one or more counterparts, with the same effect as if the parties
had signed the same document. Each counterpart so executed will be deemed to be an original, and all such counterparts will be construed together and will constitute one Agreement. 

22. Use of Viking’s Name. Except as explicitly permitted under this Agreement, neither Party shall make any public announcement relating to this
Agreement or the transactions covered by it or mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in any publication, press release, promotional material or other form of
publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this clause 27 shall not prohibit any Party from making any disclosure that is required by applicable law. In any permitted statements,
the Parties shall describe the scope and nature of their participation under this Agreement accurately and appropriately. 
 23. Academic Publications.
Publicity. Institution agrees to keep the terms of this Agreement and any SOW confidential. Institution will not make any public statement or other announcement relating to the terms of this Agreement or any SOW without the prior written
approval of Viking. 
 24. Institution and Viking recognize the traditional freedom of all scientists to publish and present promptly the results of
their research. Institution and Viking also recognize that patent rights can be jeopardized by public disclosure prior to the filing of suitable patent applications and that confidential information can be inadvertently disclosed. Institution
therefore reserves the right to make or permit to be made scholarly disclosures of any and all results, including Viking Results, pursuant to its work under this Agreement and any particular SOW, including without limitation, publication in
scholarly journals, presentations at academic and other conferences, disclosures to Institution and non-Institution scholars, and disclosures in grant and funding applications. Institution shall submit all proposed publications arising from research
under this Agreement to Viking for review before submission to a publisher. Viking shall have appropriate time, as determined by Viking, in which to review the publication, which may be extended for an additional ninety (90) days when Viking
discloses reasonable need for such extension in order to file for patent protection of Viking Results or to delete Viking Confidential Information. 

  
 11 

 25. Force Majeure. Neither party will be liable for any loss, damage or penalty resulting from delays or
failures in performance resulting from acts of God or other causes beyond such party’s reasonable control; provided, however, that (a) such party gives the other party prompt written notice of the failure to perform and the reason
therefore and uses its reasonable and diligent efforts to limit the resulting delay in its performance; and (b) no such delay or failure in performance will continue for more than sixty (60) days. In the event that such delay extends
longer than sixty (60) days, the other party may terminate this Agreement. 
 26. Export Regulations. Institution agrees to comply at all times
with any export laws, regulations, orders or other restrictions imposed by the United States government or by any other governmental entity. Notwithstanding any other provision in this Agreement or any SOW to the contrary, Institution agrees and
represents and warrants that it will not import, export or re-export, directly or indirectly, any deliverable or other Viking Results or any Institution Materials or other information or materials to any country to which such import, export or
re-export is restricted or prohibited, or as to which any such government or any agency thereof requires an export license or other governmental approval at the time of such import, export or re-export without first obtaining such license or
governmental approval. 
 In Witness Whereof, the parties have by duly authorized persons executed this Agreement as of the date first written above.

  

									
	Institution:	 	 	 	Viking, Inc.
			
	 /s/ Prof. Dr. M.M. Levi
	 		 	 /s/ Misha Dinerman, MD

	By: 	 	Prof. Dr. M.M. Levi	 		 	By: 	 	Misha Dinerman, MD
	  
	 		 	  

	Title:		Chairman of the Executive Board				Title:		Chief Operating Officer
	  
	 		 	  

	Date:		2/2/15				Date:		1/26/15
	  
	 		 	  

  
 12 

 Exhibit A 

SOW 
 Viking Materials to be Provided
by Viking under this SOW 
  

	
	 4 different compounds in 3 different concentrations
as recommended by Viking Therapeutics. Compounds will be VK0214, VK2809, and their respective active metabolites, VK0214A and VK2809A.
  

 Drug candidate to which Services relate (if applicable) 

 

	
	 VK0214, VK2809, and their active metabolites
VK0214A and VK2809A.
  

 Timetable 
  

			
	
Activity 
  
		 Timing

 

	 Evaluation of Viking compounds related to their ability to induce
ABCD2 as outlined in the description of work to be performed below.
  
		
[...***...]
  

 Payment Schedule 
  

			
	Time/Event  
		 Amount of Payment

 

	 January 27 2015

 
		
[...***...]
  

 The foregoing amounts will be due and payable by Viking within forty-five (45) days after receipt of proper invoices from
Institution. Institution is entitled to provide invoices once monthly, in arrears, with respect to events and milestones that have been completed. 

Regulatory Standards that apply 
 Best practices 

  
 A-1 

*Confidential Treatment Requested 

 Description of work to be performed: 

Initial proposal to generate knowledge for Viking compounds related to their effects on ABCD2 expression, [...***...] in control and X-ALD patient cells.
In addition, basic toxicology screening of the compounds will be performed on X-ALD cell proliferation and cell survival. 
 1) A study in cell lines from
X-ALD patients and controls to zoom in on the mechanism of action of your agent, 
  

									
	Institution:	 	 	 	Viking, Inc.
			
	 /s/ Prof. Dr. M.M. Levi
	 		 	 /s/ Misha Dinerman, MD

					
	By:	 	Prof. Dr. M.M. Levi	 		 	By:	 	Misha Dinerman, MD
	  
	 		 	  

					
	Title:		Chairman of the Executive Board				Title:		Chief Operating Officer
	  
	 		 	  

					
	Date:		2/2/15				Date:		1/26/15
	  
	 		 	  

  

  
 A-2 

*Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]